Integrative Molecular Phenotyping

KI News

Updated: 1 hour 11 min ago

What researchers think about the electronic logbook

Wed, 14/06/2017 - 13:54
Anna Jervaeus, Adjunct Lecturer at the Department of Neurobiology, Care Sciences and Society, has used KI ELN electronic research documentation since she started as a PhD student at Karolinska Institutet in 2010. A decision is expected soon to make it obligatory for all researchers at KI to document their research electronically. Anna Jervaeus introduced the KI ELN system to her research group in 2010, and today supervises a PhD student who uses it, together with other supervisors. “I think KI ELN is good. I learnt to use the system very quickly, and think it is user-friendly for the functions that I have used. It fulfils its purpose,” says Anna Jervaeus. Among the advantages, she sees the possibility to gather documents together for the research group as a whole, it’s a secure place, and has the option to lock information that has been entered. “Even though I know that I am not going to go in and fabricate something, it is good to know that I always lock the material after a certain time. It also makes it easy to get a good project structure,” she says. KI ELN is often described as produced for lab research rather than the care research that Anna Jervaeus works with. For Anna, that which is called “experiment” in the system can be data collection, manuscript work, planning documents or meeting notes, for example. “I have had to think about what is a reasonable way to divide the work, but have not experienced it as a problem that the system is not adapted to the research we are involved in. I have also had very good help and support from the KI Support Team when I have had questions,” she explains. Making KI ELN obligatory from 2018 Some KI departments will introduce electronic research documentation earlier than 2019. One of them is the Department of Odontology where it has been decided to make KI ELN obligatory from 2018. Head of Department, Mats Trulsson, says they are currently holding introductory courses on how to use the system. “We need to improve our documentation in regard to research, and we see huge advantages with KI ELN. Our entire research will be documented and properly logged, and a leader will be able to retrieve documentation even if a researcher has moved, which at the moment can pose great problems,” he comments. He believes that some researchers can experience the system as more complicated than the method they previously used, but says that this is something we just have to accept if we are to meet the requirement for a functioning research organisation. Obligatory electronic research documentation throughout the whole of KI is, he believes, an excellent idea. “It’s about confidence in research, that you can actually go back and demonstrate with documentation what you have done in research activities,” says Mats Trulsson. High-security documentation Björn Äng, associated with the Department of Neurobiology, Care Sciences and Society, started using KI ELN with a PhD student who was conducting parts of his research within the Armed Forces. High-security documentation was particularly appropriate in that case. That was about six years ago, and he believes that the system has been improved since then. “There have been times when I have been irritated – there have been bugs, and projects that had been entered seized up – but of late everything has functioned well,” he adds. Björn Äng believes KI ELN to be a good secure collection point for documents, such as ethical methods and individual study plans for PhD students. As a supervisor, he also appreciates the formalised communication – when a PhD student has started an experiment, it is sent to him for verification. “It’s good that I have to review it and fill in that I have read and understood it. This makes it more formal and transparent than an ordinary email conversation or paper version. I like that”, he says. However, he does find it slightly inflexible when creating your own structure with sub-categories in the system, and that these structures must be locked. But on the whole, he is positive to making electronic research documentation obligatory. “It is excellent. When you use the electronic logbook, you start to think and find yourself thinking that ‘Hm, yes, I should perhaps document those meeting notes’. It’s a good reminder to have your papers in order”, he comments.   Text: Sara Nilsson

Rent increases attract internal debate

Wed, 14/06/2017 - 13:43
With Karolinska Institutet’s major investments in infrastructure, especially with the new research buildings, the rents are now rapidly increasing. In addition, the laboratory-intensive activities will be required to pay more than others, from 2018, which has given rise to criticism from the academic researchers and scientists. The Biomedicum, Bioclinicum, Neo research buildings, the KM-B animal building, and the renovation of Alfred Nobel’s allé, ANA8, “The Laboratory of the Future,” will all be ready for moving into with the course of a year. “This is an absolutely essential investment,” remarks Stefan Eriksson, Vice-Dean of Infrastructure at the Karolinska Institutet. At the same time, as he admits, a lot is going on simultaneously. Sixty percent of KI’s operations will move into new premises next year, and 80 percent of the laboratory and animal research facilities will be renovated. This costs a lot of money. “When building new buildings, you have to expect that the rents will higher,” comments Stefan Eriksson. The starting point and underlying premise for the new modern research laboratories has been not only that are they required for successful research in the coming decades, but also for synergy benefits as it relates to costly equipment and reduced administrative expenses when several departments move in together. New model for rent levels to be introduced As of 2018, a new model for the setting of rent levels will be introduced with differentiated rents. The laboratory premises will cost more and will have higher rents than offices and educational premises. KI researchers have been criticising the system due to that they believe that the preconditions for experimental research are deteriorating. Among other things, the researchers do not have full access to the information concerning what funds from the external funds may be used to pay the rent. “It is unfortunate that so much has been built at the same time because this will put such a great financial burden on the University. What’s happening now is basically that the bill is being passed on to the researchers. “We should have been a little more cautious,” comments Nils-Göran Larsson, Professor of Mitochondrial Genetics and Head of Department of the Department of Medical Biochemistry and Biophysics (MBB), one of five departments moving into Biomedicum next year. Nils-Göran is also the Chair of Biomedicum’s Heads of Departments group, which rotates its Chair every six months. “When you expand Karolinska Institute’s activities to such an extent, the internal resources available to the individual researcher will be very small and experimental research will become increasingly dependent on external funding,” observes Nils-Göran Larsson. Stefan Eriksson, the Vice-Dean of Infrastructure, who was previously the head of the Department of Physiology and Pharmacology, which is moving to Biomedicum, is well-aware of and deeply involved in the strained rental situation for many research groups. Since the funding from the national government remains at the same level, more external sources of funding is needed. However, while government grants are allocated to departmental salaries and rent, many external funding sources require that the funds granted may not be used for rent. “This means the funds will not be sufficient and it is up to each department to ensure that they have a balance. Then one has to ‘shrink the suit,’ so to say, where tightening the belt can be painful,” comments Stefan Eriksson. Would like to see a helicopter perspectiv Gunilla Karlsson Hedestam, Professor at the Department of Microbiology, Tumor and Cell Biology (MTC), also questions how the research groups will be able to pay the higher rental costs. “What has happened over the past 10 years is that the research funders have come to demand more transparency with more frequent and more detailed financial reports where rental costs are rarely allowed to be included. At the same time, unallocated funds that can be used to pay the rents have become harder to find. It’s an impossible equation for many groups,” observes Gunilla Karlsson Hedestam. Professor Karlsson Hedestam would like to see a helicopter perspective on the part of KI's management in regards to the unsolvable equation concerning rental costs. “I and many others have made attempts to raise these problematic issues at KI for discussion, but one doesn't really want to touch the problem because it’s difficult to find a solution,” remarks Gunilla Karlsson Hedestam. Dean of Research Anders Gustafsson is aware that the investments in new infrastructures have hit some research groups hard. “The Board of Research at KI needs to work together with the departments in order to mitigate the effects, to the extent feasible. Relative to KI’s total income, however, the rent increases are actually not so dramatic,” comments Anders Gustafsson. A working group appointed by the Board of Research is now reviewing the models for the allocation of resources and rent compensation to the departments, which may lead to changes in the future. The working group has discussed the rent compensation for the laboratory-heavy departments on the basis of their rents, but has not yet arrived at any proposal.    Text: Stina Moritz and Madeleine Svärd Huss

The new rent model is intended to reflect actual costs

Wed, 14/06/2017 - 13:40
From 2018, the rents for laboratory rooms will be higher than for other premises at the Karolinska Institutet. The new rental model has been developed to reflect the actual costs of the new research buildings, and has been decided upon by the University Board of Karolinska Institutet. The total overall costs for Karolinska Institutet’s premises last year amounted to a total of SEK 755 million. In 2018, the figure will exceed one billion kronor, according to Lennart Ilke. As the Facilities Director, he is the head of the Facilities Office at the Karolinska Institutet, which has the responsibility for the provision of the University’s premises and which manages KI’s leasing of premises from outside owners and the internal renting to the University’s departments. The external landlords Akademiska Hus and others send their invoices to the Property Department, which then rents out the premises to the various departments. The departments in turn distribute the cost over their research groups. For many years, the philosophy behind rent-setting has been to equalise the internal rents, meaning that all institutions pay the same amount per square metre irrespective of the actual cost of the premises where the department is located. The exception is animal premises that have higher actual costs and pay a higher internal rent. Since 2014, the internal rent at the Karolinska Institutet has increased from SEK 3,350 to SEK 3,800 per square metre. In 2018, the laboratory-intensive activities will find themselves paying about SEK 4,300 per square metre on average. Proposal from the Board of Resarch A working group at the Board of Research has drawn up the proposal regarding differentiated rent-setting. Their objective was for the rents to reflect the actual costs for each square metre to a greater degree. The higher costs that a laboratory entails, compared to a normal office, justifies a higher rent. Three different factors are used to determine the level of the rent. Factor 1.0 applies to all offices and classroom/educational facilities. Laboratory premises have been assigned a factor of 1.3, which means a 30 percent higher rent, while simple basement premises have a factor of 0.5 and therefore cost one-half the normal rent. “All the new initiatives that we are now implementing, for example at Biomedicum and Neo, specifically concern laboratory-intensive research and that is what is driving the costs up. Therefore, our ambition has been both to protect the educational programme in such a way that it is not negatively impacted from having to bear increased costs due to that the research activities are getting fantastic facilities, and also to protect the research that does not need laboratory facilities,” explains Lennart Ilke. Depending upon the proportions between laboratory spaces and office areas a research group has, the average square metre rental rate between may vary research groups. “However, we will charge Biomedicum collectively, so how the departments choose to allocate the costs within Biomedicine is something that is entirely up to them,” notes Lennart Ilke. Text: Stina Moritz   A look back – from the National Board of Public Buildings to Akademiska Hus Until 1993, it was the state-owned National Board of Public Buildings (Kungl. Byggnadsstyrelsen) that managed buildings and premises for governmental authorities, including Sweden’s universities and other institutions of higher education. The educational institutions paid rent to the authority, but also received state grants to cover their rental costs. In the early 1990s, the National Board of Public Buildings was disbanded and independent state-owned limited companies such as Vasakronan and Akademiska Hus AB took over most of the buildings. “Akademiska Hus was set up at the direct request of the major universities because they needed a property owner with expertise and understanding of the universities’ needs,” notes Lennart Ilke, Facilities Director at Karolinska Institutet. At the same time, the principle for allocating state funding to the universities was revised. The universities were allowed to use their funds for research and education in the manner in which they considered best. This change meant that the universities can rent premises from any property owner they want. However Akademiska Hus came to dominate the scene because to a large extent they took over the universities’ existing premises. *** Karolinska Institutet and other universities receive basic funding from the national government. The University also applies for research funds from various funders of research. The educational programme has a compensation model per student, with different amounts depending on the student’s major. The state funding is allocated from the Board of Karolinska Institutet to the various departments via the Vice-Chancellor and the respective operational board responsible for the activities. Presently Akademiska Hus owns AB 91 percent of Karolinska Institutet’s premises; and in addition, they own the land of Campus Solna. In a few years, the proportions will shift somewhat due to that the property owner Hemsö owns the Neo research building which is under construction in Flemingsberg. Hemsö has also acquired the neighbouring Novum building. About five percent of the Karolinska Institutet’s premises are rented by the National Property Board of Sweden (SFV), Acturum and other smaller real property owners. Sources: Akademiska hus ( and the National Property Board of Sweden (SFV) ( along with the Karolinska Institutet.

Drones can increase survival from cardiac arrest

Wed, 14/06/2017 - 08:34
New research from the Centre for Resuscitation Science at Karolinska Institutet and Stockholm South General (Söder) Hospital in Sweden shows that a specially constructed drone equipped with a defibrillator can be dispatched by alarm and delivered automatically to the site of a cardiac arrest long before an ambulance arrives. The results are published in the respected medical periodical JAMA. “This study clearly shows that unmanned aircraft, drones, show great potential in being able to deliver a defibrillator long before an ambulance arrives, particularly in remote areas,” says Andreas Claesson, paramedic and lead researcher at Karolinska Institutet’s Centre for Resuscitation Science. The specially adapted ambulance-like defibrillator-equipped drone has been developed in partnership with engineers at FlyPulse AB, Trollhättan. For the present study, the drone was dispatched and automatically flown out of view of the pilot within a radius of 10 km. The drone was test-flown to the exact destination to which an ambulance had driven on 18 incidents of cardiac arrest between 2006 and 2013 in the Norrtälje municipality in Sweden; their respective arrival times were then compared. The drone, which was sent from Älmsta (Norrtälje municipality) rescue services, had a response time from alarm to being airborne of only three seconds and an average time from alarm to arrival at the scene of cardiac arrest of approximately five minutes, 16 minutes shorter than was stated in the ambulance records. An important part of the study is that the research team was given permission by the Swedish Transport Agency and the Swedish Civil Aviation Administration to fly out of sight and were therefore able to demonstrate the great potential that drones have to save lives in the event of cardiac arrest. “In areas with longer ambulance response times of up to 30 minutes, the chances of surviving a cardiac arrest are tiny,” explains Mr Claesson. “Drones able to deliver defibrillators can reach the patient inside the first few minutes and are thus a new and important complement to existing emergency services. With an early shock from a defibrillator within the first 3-5 minutes after cardiac arrest, up to 70 per cent of patients can survive the event.” The project was financed with a grant from the Stockholm County Council Innovation Fund. Publication “Time to Delivery of an Automated External Defibrillator Using a Drone for Simulated Out-of-Hospital Cardiac Arrests vs Emergency Medical Services”, Andreas Claesson, Anders Bäckman, Mattias Ringh, Leif Svensson, Per Nordberg, Therese Djärv, Jacob Hollenberg JAMA, 13 juni 2017, 317(22):1-3.

Lithium protects against suicide

Fri, 09/06/2017 - 15:45
Suicidal behaviour decreases among individuals with bipolar disorder during periods of lithium medication, according to an extensive register-based study conducted at Karolinska Institutet in Sweden. The results are published in The American Journal of Psychiatry. More than one percent of the world’s population is affected by bipolar disorder. The disease is characterised by alternating periods of depression and elevated mood (mania). Medication with lithium and valproate prevents manic phases and has mood-stabilizing effects. It is known that people with bipolar disorder have a high risk of committing suicide, but whether the drugs reduce the risk of suicide has not been sufficiently investigated. Researchers at Karolinska Institutet have, therefore, conducted an extensive register-based study. Many suicides could be avoided ”We now strongly augment the existing evidence that lithium treatment is protective against suicide attempts and suicide”, says Professor Paul Lichtenstein at Karolinska Institutet’s Department of Medical Epidemiology and Biostatistics. ”We estimate that more than ten per cent of attempted or completed suicides could have been avoided if these individuals had been continuously taking lithium during the study period”. The study was performed in collaboration with the University of Gothenburg and included more than 51,000 individuals with bipolar disorder from the Swedish National Patient Registry over an eight-year period (2006-2013). During this period, 10,648 suicide-related events occurred. All participants in the study were compared to themselves during periods with and without medication with lithium and valproate, respectively. The risk of suicide-related events was reduced by 14 per cent while individuals were receiving lithium, as compared with the same individuals while not receiving lithium. Lithium medication has decreased steadily The study also demonstrates that valproate, the most common alternative to lithium, probably has no effect on suicidal behaviour. Lithium medication has decreased steadily in recent years in Sweden. Paul Lichtenstein believes that the results of the study are of relevance for clinical decisions. ”When a doctor is trying to find the best pharmacological treatment for the patient, the anti-suicidal effect of lithium should be taken into consideration, especially for patients with suspected suicidal intentions”, says Paul Lichtenstein. The study was financed with grants from the Swedish Research Council, the Swedish Council for Working Life and Social Research, the Swedish foundation for Strategic Research, and the China Scholarship Council. No commercial interests have been reported. Publication ‘Suicidal Behavior During Lithium and Valproate Medication: A Within-individual Eight Year Prospective Study of 50,000 Patients With Bipolar Disorder’, Jie Song, Arvid Sjölander, Erik Joas, Sarah E. Bergen, Bo Runeson, Henrik Larsson, Mikael Landén, Paul Lichtenstein. The American Journal of Psychiatry, online 9 June 2017.

Fewer relapses in schizophrenia with long-acting injections

Thu, 08/06/2017 - 14:33
The risk of relapse among patients with schizophrenia differs depending on what drug is administered, suggests a register study from Karolinska Institutet in Sweden published in JAMA Psychiatry. Clozapine and long-acting injections were linked to fewer re-admissions to hospital than other antipsychotics. Antipsychotic treatment is used to prevent relapse into the mental disorder known as schizophrenia. There are several kinds of antipsychotic drugs today but it has been controversial whether there is any clinically relevant difference between the various treatments when it comes to preventing relapses. About 30,000 patients studied To find out, researchers at Karolinska Institutet carried out a register-based study of 29,823 Swedish patients who were aged between 16 and 64 in 2006 and who were diagnosed with schizophrenia between 2006 and 2013. Every individual was used as his/her own control to eliminate selection bias that might otherwise occur, because patients who are more seriously ill are often treated with other drugs than those who are not as ill. The researchers then looked at what medications the patients had been used and if they had been admitted to hospital again, attempted suicide, stopped taking their medication or died.   “We saw considerable differences between the various antipsychotic treatments. Clozapine and long-acting injections were linked to the best results,” says Jari Tiihonen, specialist doctor and professor at Karolinska Institutet’s Department of Clinical Neuroscience.   20-30 per cent lower risk of re-admission The risk of the patients having been re-admitted to hospital was about 20-30 per cent lower if the patients were given long-acting injections of antipsychotic drugs compared to if the patients received the same medication but orally. This difference was in particular observed in those patients experiencing their first episode.   “Our findings indicate that the risk of the patient being admitted to hospital again varies between different antipsychotics,” says Jari Tiihonen.   The study has been finalised with the help of funds from Janssen-Cilag. Jari Tiihonen has worked as a consultant for Fimea (Finnish Medicines Agency), AstraZeneca, Bristol-Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Janssen-Cilag, Lundbeck and Organon. Publication 'Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia' Jari Tiihonen, Ellenor Mittendorfer-Rutz, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen and Heidi Taipale JAMA Psychiatry, online 7 June 2017, doi:10.1001/jamapsychiatry.2017.1322

New possible target for cancer treatment

Wed, 07/06/2017 - 15:21
Scientists at Karolinska Institutet in Sweden report that cancer cells and normal cells use different ‘gene switches’ in order to regulate the expression of genes that control growth. In mice, the removal of a large regulatory region linked to different types of cancer caused a dramatic resistance to tumour formation, but did not affect normal cell growth. The findings, published in the scientific journal eLife, highlight the possibility of developing highly specific cancer drugs with fewer side effects. Humans have close to 20,000 genes to carry out all the functions in a cell. The genes make up only 2 per cent of a cell’s total DNA. What makes us different from one another is mainly the variation in the remaining 98 per cent of our DNA. The variation is believed to alter the activity of regulatory regions or ‘gene switches’ (enhancer elements), which control the activity levels of genes in a cell. It is this variation that is mainly responsible for making individuals more or less susceptible to the development of diseases such as cancer. Gene switch linked to many cancer-related deaths In the current study, using mice, scientists have analysed a large gene switch region that is linked to the risks of developing many different types of cancer, including prostate, breast, colon, bladder and thyroid cancers as well as chronic lymphocytic leukaemia and myeloma. The variation in this region accounts for far more cancer-related deaths than inherited mutations in well-known cancer-causing genes. It is currently unclear why cancer cells use these particular switches, and whether they have any function in normal cells. The scientists turned the gene switches off by removing this region from the mouse genome, and found that its loss has no effect on normal mouse development and growth. Although removing the gene switch region brought down the levels of the nearby cancer gene Myc, the mice remained normal and healthy. However, the mice were strongly resistant to the formation of breast tumours and tumours in the intestine. Can lead to highly specific treatments According to the scientists, these results show that normal cells can function and divide without the genetic elements that are needed for the growth of cancer cells. The study therefore highlights the possibility of developing highly specific cancer drugs. “Since we find that the growth of normal and cancer cells is driven by different gene switches, we can in principle aim at switching off the system for growth only in the cancer cells without any harmful effect on the growth of normal cells. This can lead to the development of highly specific approaches for cancer therapy with much lower toxic side effects”, says Professor Jussi Taipale at Karolinska Institutet’s Department of Medical Biochemistry and Biophysics who led the study. The work was supported by the Center for Innovative Medicine at Karolinska Institutet, the Knut and Alice Wallenberg Foundation and the EU FP7 Health project SYSCOL. Publication “Mice deficient of Myc super-enhancer region reveal differential control mechanism between normal and pathological growth” Kashyap Dave, Inderpreet Sur, Jian Yan, Jilin Zhang, Eevi Kaasinen, Fan Zhong, Leander Blaas, Xiaoze Li, Shabnam Kharazi, Charlotte Gustafsson, Ayla De Paepe, Robert Månsson and Jussi Taipale eLife online 6 June 2017

Unexpected mechanism behind chronic nerve pain

Fri, 02/06/2017 - 14:09
It has long been assumed that chronic nerve pain is caused by hypersensitivity in the neurons that transmit pain. Researchers at Karolinska Institutet in Sweden now show that another kind of neuron that normally allows us to feel pleasant touch sensation, can switch function and instead signal pain after nerve damage. The results, which are presented in the journal Science, can eventually lead to more effective pain treatments. Severe, treatment-demanding chronic nerve pain is a common condition but the drugs available have, at best, only some efficacy. Since the mechanisms behind nerve pain are largely unknown, the pharmaceutical industry has encountered major setbacks in the development of new drugs. It was previously assumed that certain sensory neurons only transmit pleasant tactile sensations, while other neurons specialise to transmit pain. During chronic nerve pain, normal touch can cause pain, but how this happens has remained a mystery. Scientists at Karolinska Institutet have now discovered that a small RNA molecule (microRNA) in sensory neurons regulates how touch is perceived. Upon nerve damage, levels of this molecule drop in the sensory neurons, which results in raised levels of a specific ion channel that makes the nerve cells sensitive to pain. Could explain different pain thresholds “Our study shows that touch-sensitive nerves switch function and start producing pain, which can explain how hypersensitivity arises,” says Professor Patrik Ernfors at Karolinska Institutet’s Department of Medical Biochemistry and Biophysics. “MicroRNA regulation could also explain why people have such different pain thresholds.” The drug substance gabapentin is often used to treat nerve pain, even though the mechanism of action has not been known. The new study shows that gabapentin operates in the touch-sensitive neurons and blocks the ion channel that increases when microRNA levels decrease. Yet it is still around only half of all patients who respond positively to the treatment. “Nerve pain is a complex condition with several underlying mechanisms,” says Professor Ernfors. “What’s interesting about our study is that we can show that the RNA molecule controls the regulation of 80 per cent of the genes that are known to be involved in nerve pain. My hope, therefore, is that microRNA-based drugs will one day be a possibility.” Research on mice and human tissue The research was primarily conducted on mice but also verified in tests on human tissue, where low microRNA levels could be linked to high levels of the specific ion channel and vice versa, suggesting that the mechanism is the same in humans. “It’s vital that we understand the mechanisms that lead to chronic nerve pain so that we can discover new methods of treatment,” says Professor Ernfors. “The pharmaceutical companies have concentrated heavily on substances that target ion channels and receptors in pain neurons, but our results show that they might have been focusing on the wrong type of neuron.” The study was financed by a USCPRC Award, CERC Program, PAINCAGE, FP7 integrated project, an ERC advanced grant (PainCells), the Swedish Research Council, StratNeuro, the Swedish Brain Foundation, the Knut and Alice Wallenberg Foundation, the Swedish Cancer Society, the Torsten Söderberg Foundation, the Wellcome Trust and Karolinska Institutet. Publication “MiR-183 cluster scales mechanical pain sensitivity by regulating basal and neuropathic pain genes” Changgeng Peng, Lili Li, Ming-Dong Zhang, Carolina Bengtsson Gonzales, Marc Parisien, Inna Belfer, Dmitry Usoskin, Hind Abdo, Alessandro Furlan, Martin Häring, Francois Lallemend, Tibor Harkany, Luda Diatchenko, Tomas Hökfelt, Jens Hjerling-Leffler & Patrik Ernfors Science, online 1 June 2017. Doi: 10.1126/science.aam7671

High-sensitivity assay gives more reassurance to chest pain patients

Tue, 30/05/2017 - 17:11
For some time now, patients in Sweden’s emergency clinics complaining of chest pain have been evaluated using the “high-sensitivity troponin T” assay. In a large-scale registry study published in the Journal of the American College of Cardiology scientists at Karolinska Institutet show how this more sensitive analytical method has improved evaluation for these patients. Since its introduction, fewer patients diagnosed with “unspecified chest pain” suffer a heart attack or die after being sent home. Chest pain is one of the most common reasons for emergency medical care. Sometimes the pain can be related to a heart attack, but most of the time the cause of the problem cannot be identified and most patients are sent home with an “unspecified chest pain” diagnosis. However, a few of these people will suffer a heart attack, others will have to undergo unplanned revascularisation, and still others will die within 30 days. The difficulty lies in ascertaining who these patients are when they go to an emergency unit with a chest pain complaint. To rule out myocardial infarction, doctors normally check the patients’ ECG and a blood test or the cardiac biomarkers troponin T or I. In recent years, however, a new and more sensitive assay has been introduced at Swedish hospitals. The method is called high-sensitivity troponin T, which has been shown by previous studies to be more diagnostically accurate, although whether this accuracy applies to clinical procedures has not been known. 65,000 patients studied To discover if high-sensitivity troponin T is associated with a lower incidence of cardiovascular events, the researchers conducted a large-scale registry study of 65,000 patients with unspecified chest pain who had been discharged from 16 Swedish emergency clinics between 2006 and 2013 in connection with the introduction of the new method. They found that the risk of suffering a serious cardiovascular event within 30 days of returning home was much lower in patients discharged from an emergency clinic when the new method was in use than in those examined with the old one. The percentage of those subsequently suffering a heart attack, dying or undergoing unplanned revascularisation dropped from 0.9 to 0.6 per cent. “Our results are of interest to other countries such as the USA, which is about to change its methods,” says Per Svensson, associate professor and senior lecturer at Karolinska Institutet’s Department of Medicine in Solna. Increased risk amongst admitted patients However, amongst the patients who had been discharged from hospital after being admitted for an unspecified chest pain diagnosis, the risk of suffering serious events increased after the change in method. In this group, 7.2 per cent of patients with the new method in use were affected, compared with 3.4 per cent who were examined in the former way. These particular patients also had a higher risk profile after the change in method. “We may conclude from the results of our study that examination using high-sensitivity troponin is associated with fewer serious cardiac events and an improvement in risk profile for patients released from emergency clinics with unspecified chest pain,” says Dr Svensson. “The opposite was observed in patients sent home after admission to hospital, which suggests that high-risk patients are identified and hospitalised more frequently. We therefore conclude that high-sensitivity troponin has helped to improve the evaluation of emergency patients with unspecified chest pain.” The study was financed by Karolinska Institutet. Publication “Outcomes in Patients With Chest Pain Discharged After Evaluation Using a High-Sensitivity Troponin T Assay” Atosa Nejatian, Åsa Omstedt, Jonas Höijer, L.O. Hansson, Therese Djärv, Kai M. Eggers, Per Svensson Journal of the American College of Cardiology (JACC), 30 May 2017, 69(21):2622-2630, doi:10.1016/j.jacc.2017.03.586

How fear can develop out of others’ traumas

Mon, 29/05/2017 - 14:27
What happens in the brain when we see other people experiencing a trauma or being subjected to pain? Well, the same regions that are involved when we feel pain ourselves are also activated when we observe other people who appear to be going through some painful experience. This is shown in a study from Karolinska Institutet published in Nature Communications. But we are sensitive to different degrees to learning fear from other people and one explanation would appear to be found in the endogenous opioid system. Seeing others express pain or anxiety can give us important information about things around us that are dangerous and should be avoided. Sometimes, however, we can develop fear of situations that, rationally speaking, are not dangerous. The opioid system is supposed to alleviate pain and fear but it does not work as effectively in all of us, which might be one of the reasons why some people develop anxiety syndrome merely by seeing others experience a trauma. The opioid system affects how sensitive we are “Some people are over-sensitive to this form of social learning. Our study shows that the endogenous opioid system affects how sensitive we are and may explain why some people develop post-traumatic stress disorder (PTSD) merely by observing others who are experiencing traumatic events. After terror attacks, sensitive people might be afraid even if they themselves were not present,” says main author Jan Haaker, associated researcher at Karolinska Institutet’s Department of Clinical Neuroscience. In a double-blind study, the researchers altered the brain’s internal chemistry in 22 healthy subjects by using a pharmaceutical substance to block the opioid system. 21 subjects were given an inactive placebo. The subjects then watched a video where other people were subjected to electric shocks. Continued to react as if they were surprised The brain normally updates its knowledge of danger based on whether we are surprised, but when the opioid system was blocked, the people continued to react as if they were surprised even though they knew the electric shock would come. And the response was amplified even when they continued to watch other people being subjected to shocks. The response increased in regions of the brain such as the amygdala, the periaqueductal gray and the thalamus, which seems to indicate that the same functions as in self-perceived pain were involved. Communication also increased between these and other regions of the brain that were previously linked to the ability to understand other individuals’ experiences and thoughts. “When the people participating in the experiment were themselves subjected to threatening stimuli that they had previously associated with other people’s pain, they perspired more and displayed more fear than those who had been given a placebo. This enhanced learning was even visible three days after the social learning episode,” says research team leader Andreas Olsson, senior lecturer at Karolinska Institutet’s Department of Clinical Neuroscience. The study contributes to greater understanding of the psychology behind fear. The researchers hope that the new findings will eventually mean that people with anxiety conditions will be able to be given better, more individual-adapted clinical help. The study was financed by the European Research Council (ERC), the Knut and Alice Wallenberg Foundation and the German Research Foundation (DFG). Publication ”Endogenous opioids regulate social threat learning in humans” Jan Haaker, Jonathan Yi, Predrag Petrovic and Andreas Olsson Nature Communications, online 25 May 2017. doi:10.1038/ncomms15495

The brain detects disease in others even before it breaks out

Wed, 24/05/2017 - 13:44
The human brain is much better than previously thought at discovering and avoiding disease, a new study led by researchers at Karolinska Institutet in Sweden reports. Our sense of vision and smell alone are enough to make us aware that someone has a disease even before it breaks out. And not only aware – we also act upon the information and avoid sick people. The study is published in the scientific journal Proceedings of the National Academy of Sciences (PNAS). The human immune system is effective at combating disease, but since it entails a great deal of energy expenditure disease avoidance should be part of our survival instinct. A new study now shows that this is indeed the case: the human brain is better than previously thought at discovering early-stage disease in others. Moreover, we also have a tendency to act upon the signals by liking infected people less than healthy ones. “The study shows us that the human brain is actually very good at discovering this and that this discovery motivates avoidance behaviour,” says principal investigator Professor Mats Olsson at Karolinska Institutet’s Department of Clinical Neuroscience. Measured brain activity By injecting harmless sections of bacteria, the researchers activated the immune response in participants, who developed the classic symptoms of disease – tiredness, pain and fever – for a few hours, during which time smell samples were taken from them and they were photographed and filmed. The injected substance then disappeared from their bodies and with it the symptoms. Another group of participants were then exposed to these smells and images as well as those of healthy controls, and asked to rate how much they liked the people, while their brain activities were measured in an MR scanner. They were then asked to state, just by looking at the photographs, which of the participants looked sick, which they considered attractive and which they might consider socialising with. “Our study shows a significant difference in how people tend to prefer and be more willing to socialise with healthy people than those who are sick and whose immune system we artificially activated,” says Professor Olsson. “We can also see that the brain is good at adding weak signals from multiple senses relating to a person's state of health”. Opposite effect in close relationships This he sees as biological confirmation of the argument that survival naturally entails avoiding infection. “Common sense tells us that there should be a basic behavioural repertoire that assists the immune system. Avoidance, however, does not necessarily apply if you have a close relationship with the person who is ill,” says Professor Olsson. “For instance, there are few people other than your children who you’d kiss when they have a runny nose. In other words, a disease signal can enhance caring behaviour in close relationships. With this study, we demonstrate that the brain is more sensitive to those signals than we once thought.” The research has been carried out in collaboration with several parties, especially with the Stress Research Institute at Stockholm University. The study was supported by the Swedish Research Council, the Swedish Foundation for Humanities and Social Sciences, the Knut and Alice Wallenberg Foundation and Deutscher Akademischer Austauschdienst. Publication “Behavioral and neural correlates to multisensory detection of sick humans” Christina Regenbogen, John Axelsson, Julie Lasselin, Danja K. Porada, Tina Sundelin, Moa G. Peter, Mats Lekander, Johan N. Lundström, Mats J. Olsson PNAS, Online 22 May 2017. doi: 10.1073/pnas.1617357114

Making biological drugs with spider silk protein

Wed, 24/05/2017 - 13:13
Researchers at Karolinska Institutet in Sweden have managed to synthesise lung surfactant, a drug used in the care of preterm babies, by mimicking the production of spider silk. Animal studies reveal it to be just as effective as the biological drugs currently in clinical use. The study is published in Nature Communications. Surfactant revolutionised the care of preterm babies by reducing the surface tension in their pulmonary alveoli and allowing them to be inflated at the moment of birth. Curosurf, the most globally widespread drug, was developed by scientists at Karolinska Institutet in the 1970s and 1980s. The drug is produced by the isolation of proteins from pig lungs, a process that is expensive, complicated and potentially risky. Researchers at Karolinska Institutet and their colleagues from the University of Riga amongst other institutions, have now developed a surfactant drug that can be produced much more simply and cheaply using spider protein. “The manufacturing process is based on the method spiders use to keep their extremely easily aggregated proteins soluble for silk-spinning,” explains Professor Jan Johansson at Karolinska Institutet’s Department of Neurobiology, Care Sciences and Society. “We chose to produce lung surfactant protein C because it is probably the world’s most aggregation-inclined protein.” Used a part of the spider protein By applying this method, the researchers have managed to produce a range of potential biological drugs using the part of the spider protein that ensures that the proteins remain soluble, namely the N-terminal domain. “We had bacteria produce this part of the protein and then linked it to different protein drug candidates,” says docent Anna Rising at Karolinska Institutet’s Department of Neurobiology, Care Sciences and Society who co-led the study with Professor Johansson. Compared with the approved drug The researchers also compared their synthetic lung surfactant with the biological analogue currently on the market and found it equally effective at reducing the surface tension in an animal model of neonate respiratory disorders. “Since this production method is much simpler and cheaper, it might one day be possible to use our synthetic lung surfactant to treat more lung diseases than just preterm babies,” adds Professor Johansson. “The method will also hopefully enable the production of other biological drugs.” The study was primarily financed by the Swedish Research Council and was performed in collaboration with the Italian pharmaceutical company Chiesi Farmaceutici. Publication “Efficient protein production inspired by how spiders make silk” Nina Kronqvist, Médoune Sarr, Anton Lindqvist, Kerstin Nordling, Martins Otikovs, Luca Venturi, Barbara Pioselli, Pasi Purhonen, Michael Landreh, Henrik Biverstål, Zigmantas Toleikis, Lisa Sjöberg, Carol V. Robinson, Nicola Pelizzi, Hans Jörnvall, Hans Hebert, Kristaps Jaudzems, Tore Curstedt, Anna Rising & Jan Johansson Nature Communications , online 23 May 2017

Response to former KI vice-chancellor’s statement in Läkartidningen

Wed, 24/05/2017 - 08:32
Comment: Läkartidningen has published an interview with KI’s former vice-chancellor Harriet Wallberg following a letter she sent to KI demanding corrections to Sten Heckscher’s report on the Macchiarini case. In the interview Wallberg makes reference to a conversation with KI’s acting vice-chancellor and university director. The KI management responds here to her claims. KI’s university director and acting vice-chancellor were invited by Harriet Wallberg to a meeting following the presentation of Sten Heckscher’s report. It was pointed out at the time that the investigation was an external one commissioned by the University Board, where the investigator himself would be accountable for the content. At the same time, it was put forward that KI cannot rule out the possibility of errors in the report since it had not undergone a quality check. Contrary to Wallberg’s claim in Läkartidning, no flaws were ever found in Sten Heckscher’s report.

Interview: Ole Petter Ottersen on becoming KI’s new vice-chancellor

Tue, 23/05/2017 - 09:22
The expectations are high. Everyone, externally as well as internally, are asking themselves how Ole Petter Ottersen is going to lead Sweden’s most talked-about university once he takes up office as vice-chancellor of Karolinska Institutet this August. After KI’s annus horribilis, now that the university has devoted a great deal of time and energy to clearing up in the wake of the Macchiarini case many people are hoping for a fresh start. The vice-chancellor-elect is at once humble and optimistic. “We now have to make sure to use the crisis for something positive and learn from it,” says Ole Petter Ottersen. “I wouldn’t have accepted the job if I hadn’t thought that something good can come out of all this.” He makes a point of praising the work done by the acting vice-chancellor and that it means a great deal to be working alongside Karin Dahlman-Wright as pro-vice-chancellor. However, he will also be inserting new issues high up his agenda the moment he settles down at his desk. The first concerns job satisfaction. “The question of how to create job satisfaction in an organisation reeling from such challenges is one that occupies my mind a great deal, and I’m prepared to discuss it with the management, deans and departments. A lot of amazing things are happening at Karolinska Institutet, especially all the new buildings and opportunities that are emerging here. All the same, I think that academic excellence must be balanced with a solid working culture and ethical preparedness, for I think that then the university will have a fantastic future ahead of it,” he says. Leadership in Norway and internationally Professor Ottersen has a sterling academic CV and long experience of leadership in and outside Norway. He is a doctor, professor of medicine, brain researcher and, since 2009, rector of Oslo University. One could say that Professor Ottersen has taken the classic career route in his own Alma mater, as the former head of the Anatomy Department, dean of research and the Medical Faculty, and director of one of Norway’s first Centres of Excellence, the Centre for Molecular Biology and Neuroscience. In this sense he is not unlike previous vice-chancellors at KI. But what sets him apart from his predecessors is that he is to be vice-chancellor of a different university to the one he was “raised” at. Professor Ottersen is experienced in leading international university evaluations and is the former chair of the ERC, European Research Council’s Advanced Grants panel and the current chair and member of the newly established Guild of Research Intensive Universities. Amongst many other positions. Be that as it may, he admits that taking on the rectorate of KI will be a steep uphill climb, and he will have to go home to do some studying over the summer on Swedish law, on the rules governing the exercise of public authority, and on how the academic sector in Sweden operates. But he also has to gradually familiarise himself with a completely new organisation. How do you intend to inspire confidence in the employees? “I really believe in being honest and open, I suppose that’s the main thing, as is having a clear vision about where the organisation is heading,” he says. Partnership and education Aside from job satisfaction, his other priorities were proclaimed in the policy statement he presented to Karolinska Institutet when he was still being proposed as the sole final candidate for the vice-chancellor’s office. He now mentions three of them: “The most important thing is how to get the best possible partnership in place between Karolinska Institutet, the hospital and Stockholm County Council. I’m happy to see that the “Akademiska stråket” link will soon be completed so that Solnavägen will no longer be a physical barrier between the university and the university hospital. And it goes without saying that the two campuses in Flemingsberg and Solna should work well together. I also want to make sure that the status of education is raised. Karolinska Institutet’s goal is to be a world-leading research university and should also aim to be top-ranking in education too.” Oslo University has eight faculties. How different will it be to lead a medical university? “It’s surprising how many of the challenges facing KI are similar to those we have in Oslo, where we’ve created a similar partnership with the Regional Health Authority. We’ve also put a lot of work into strengthening education. So even though Karolinska Institutet is a completely different university, I’m not a stranger to these kinds of challenge. But of course, it’s a major undertaking that will require me to really get to know the organisation.” Professor Ottersen points out that even if KI is a medical university, he will actively encourage more multidisciplinary work and is keen to see closer and broader cooperation with the Royal Institute of Technology, with other universities – including Stockholm and Uppsala – and, last but not least, with Nordic medical institutions. How do you plan to go about strengthening education? “I believe that teaching at a leading university like Karolinska Institutet must carry a high status and that you need to have examinations that in themselves are part of the learning process and to go through the study programmes to see how the degrees can yield more benefit to the students. Digital degrees are often in demand from the students and this is something we’ve put a lot of effort into at Oslo University. I don’t know how far KI has come, but it’s an important area to focus on.” Why is education so often in the shadow of research? “All universities put a premium on research because it has higher kudos,” says Professor Ottersen. “But raising the status of education pays off in research terms too. Both areas benefit from it. After all, we source a lot of our researchers from amongst our own students, and it’s useful to get students involved in research as much as possible.” Professor Ottersen has himself taught for over 30 years and is a much cited researcher in his field. “I think that the combination is inspiring,” he says. “It’s a wonderful thing to research and to pass your results onto the students and get their response. It’s not without reason that education and research belong together. They’re not rivals.” Blogger and public debater His own research has focused on the brain and the neurotransmitters that allow nerve cells to “talk” to each other. He has also researched how water is transported in the brain. This said, he devotes some of his time to a completely different field: “I’m very interested in global health and have led the Lancet-University of Oslo Commission on Global Governance for Health, which has been looking at health inequality around the world and the mechanisms driving it.” Professor Ottersen is a well-known blogger and public debater in Norway. He believes that research policy should operate with a degree of consistency, and often talks about the value of foresight and endurance to research success and of having strong research funders and a higher basic appropriation for universities. “Research is time consuming, and it can sometimes take up to fifteen years for you to arrive at the goal of your investigation. Financing is very much governed by what are seen as more or less acute needs and you have to make sure to keep changing the research financing objectives.” He also sticks his neck out on the issue of whether universities should recruit researchers at the top of their careers or invest in junior doctoral graduates and postdocs by creating attractive internal career pathways. “I’ve been saying this for a long time, from the perspective of Oslo University, that the best way to recruit is to target young talent. This is a sound recruitment strategy and allows you to build strong subject fields.” The final question of the interview concerns the motto that Karolinska Institutet should have if Oslo University’s is “We are reaching for the stars”. But he chooses not to say. “It’s not up to me as vice-chancellor to dictate what the university’s motto will be. But it’s good if it signals ambition, because high ambitions are the most important driver of excellence – or frontline research, as I prefer to say. However, the ambitions must be realistic and can only be achieved brick by brick – never by taking shortcuts. I think it’s good to have the ambition to reach for the stars, to do your best to reach a little beyond your grasp.”   Text: Madeleine Svärd Huss Photo: Gustav Mårtensson

Preterm birth linked to higher risk of heart failure

Tue, 23/05/2017 - 08:59
Babies born preterm run a higher risk of heart failure during childhood and adolescence than those born at full term, researchers at Karolinska Institutet in Sweden report. The registry-based study is published in The Journal of the American College of Cardiology (JACC). More and more babies survive increasingly preterm births. Babies born prematurely are exposed to life outside the womb at a time when their organs are yet to fully mature and their bodies are not entirely prepared for the radical transition from fetus to neonate. In recent years, scientists have become all the more interested in the consequences of preterm birth on, amongst other things, cardiovascular health in young adults. Complementing previous studies indicating a higher risk of hypertension, stroke and fatal cardiovascular disease, researchers at Karolinska Institutet have now uncovered a hitherto unknown connection between preterm birth and heart failure in a registry study of 2.6 million individuals born between 1987 and 2012. “We found that the risk of heart failure was higher for individuals born preterm, and inversely correlated with duration of pregnancy, in that the earlier you’re born, the greater the risk,” explains lead author Hanna Carr, doctoral student at Karolinska Institutet’s Department of Medicine in Solna. The study shows that children born before the 28th week are 17 times more likely to suffer heart failure than those born at full term. Individuals born a little later – in weeks 28 to 31 – ran just over three times the risk. This correlation held when children with birth defects were excluded from the analysis and other possible determinants, such as birth weight, socioeconomic situation and parental heart conditions, were controlled for. The results corroborate earlier studies indicating abnormal development of the cardiovascular system in people born prematurely. The researchers point out, however, that heart failure is very rare in children and young adults, so the risk of developing the condition at a young age is very small, even for people born prematurely. “It could be the case that the higher risk of heart failure remains when they grow older, in which case more people will be affected as heart failure is much more common in older people,” says associate professor Anna-Karin Edstedt Bonamy, paediatrician, who led the project. “In general the risk of heart failure can be reduced by adopting a healthy lifestyle, including refraining from tobacco use, keeping physically active, minimising your alcohol consumption and occasionally checking your blood pressure.” The study was financed by Stockholm County Council Research Service, the Karolinska Institutet Clinical Scientist Training Programme and the Swedish Heart and Lung Foundation. Publication Preterm birth and risk of Heart Failure Up to Early Adulthood Hanna Carr, Sven Cnattingius, Fredrik Granath, Jonas F. Ludvigsson, Anna-Karin Edstedt Bonamy, Journal of the American College of Cardiology, online 22 May 2017.

New findings on formation and malformation of blood vessels

Tue, 23/05/2017 - 08:54
In diseases like cancer, diabetes, rheumatism and stroke, a disorder develops in the blood vessels that exacerbates the condition and obstructs treatment. Researchers at Karolinska Institutet now show how blood vessels can normally change their size to create a functional circulatory system and how vascular malformation during disease can occur. In the study, published in Nature Cell Biology, the researchers managed to treat vascular malformation in mice, a discovery of potential significance to numerous vascular diseases. A healthy body has a perfect balance of arteries, capillaries and veins that allow the blood to reach every cell in the body and that form what is called the “vascular tree”. New blood vessels are formed by endothelial cells, which normally coat the inside of blood vessels and which organise themselves into tubes and mature, along with other cells, into arteries, capillaries or veins. Throughout a person’s life, the vascular tree has to adapt its branches to the changing needs of body tissue, such as during growth, muscle building or wound healing. However, there are diseases that affect the endothelial cells in a way that throws the vascular tree out of balance, which exacerbates the disease and often causes haemorrhaging. In cancer, for example, it is known that the vessels leak and direct shunts form between arteries and veins, preventing drugs from reaching the tumour. To understand how arteries, veins and capillaries are created – and how the process malfunctions in the presence of disease – the researchers studied normal vascular formation and the inherited Osler-Weber-Rendu disease (HHT), which is characterised by vascular malformation and repeated haemorrhaging, with an increased risk of stroke. By switching signals on and off in the endothelial cells of genetically manipulated mice, the researchers could describe how the protein Endoglin controls vascular formation and malformation. They found that the protein acts like a sensor that detects blood flow and tells the endothelial cells to organise themselves into veins, capillaries or arteries as necessary. Cells that lacked the protein were less able to form arteries. The researchers were also able to reduce vascular malformation in the genetically manipulated mice. “Our findings contribute to the understanding of fundamental biological processes that explain how the vascular tree is formed and what causes vascular malformation,” says Lars Jakobsson, assistant professor at Karolinska Institutet’s Department of Medical Biochemistry and Biophysics. “Drugs with a similar effect as one of those we tested are currently used to treat patients with inherited vascular malformation but are still under evaluation. Now we have another candidate and a more nuanced idea of how it works. We are now in a better position to control the formation and malformation of blood vessels and thus their function, which can eventually lead to improved treatments for a number of diseases.” The researchers at Karolinska Institutet also contributed to a parallel study, published in the same issue of Nature Cell Biology, describing how blood flow influences endothelial cell size that in turn affects vessel identity and malformation. The studies were financed by several bodies, including the William K. Bowes, Jr. Foundation, the Swedish Research Council, the Swedish Cancer Society, Karolinska Institutet, the Jeansson Foundations and the Magnus Bergvall Foundation. Publications Endoglin prevents vascular malformation by regulating flow-induced cell migration and specification through VEGFR2 signalling. Yi Jin, LarsMuhl, Mikhail Burmakin, YixinWang, Anne-Claire Duchez, Christer Betsholtz, Helen M. Arthur and Lars Jakobsson. Nature Cell Biology, online 22 May 2017 Endoglin controls blood vessel diameter through endothelial cell shape changes in response to haemodynamic cues. Wade W. Sugden, RobertMeissner, Tinri Aegerter-Wilmsen, Roman Tsaryk, Elvin V. Leonard, Jeroen Bussmann, Mailin J. Hamm, Wiebke Herzog, Yi Jin, Lars Jakobsson, Cornelia Denz, Arndt F. Siekmann. Nature Cell Biology, online 22 May 2017

Preparing for the management transition

Mon, 22/05/2017 - 14:28
Karolinska Institutet’s vice-chancellor-elect, Ole Petter Ottersen, has held his first day of meetings with representatives of the organisation, including Acting Vice-Chancellor Karin Dahlman-Wright, the chair of the university board Mikael Odenberg, the deans and University Director Per Bengtsson. He also attended a scientific meeting in the Nobel Forum. Ole Petter Ottersen takes over as vice-chancellor on 1 August 2017, at which point Karin Dahlman-Wright resumes her ordinary role as pro-vice-chancellor. Amongst the issues they discussed during his visit, which took place on 19 May, were the responsibilities that fall to them and how they are to be shared. “I’m looking forward to being a pro-vice-chancellor again, which is the job I actually applied for,” says Karin Dahlman-Wright, who admits that it came as a surprise to everyone, not least to her, for her to end up after a couple of days in the middle of all the turmoil that led to her stepping in as acting vice-chancellor. After the then vice-chancellor resigned his office following the storm of criticism over the Macchiarini case, Karolinska Institutet has been engaged not only in investigations and remedial action plans but also in a recruitment process to find a new vice chancellor. In April, the government appointed Ole Petter Ottersen as vice-chancellor at Karolinska Institutet, the only final candidate that the University Board had put forward. Starts formally on 1 August Ole Petter Ottersen will be quitting the rectorate of Oslo University this summer, but stresses that he will not have any formal role at KI before 1 August 2017. “But I’m hoping for many discussions before that,” he says. “I’ve got a very sharp learning curve to follow, given all I need to know about – Swedish law, the academic sector and, not least, the culture. It’s incredibly inspiring.” “It’s also imperative for me that Karin knows the university so well and is continuing as pro-vice-chancellor. I’m looking forward very much to working with her.” As the newly appointed pro-vice-chancellor the idea for Karin Dahlman-Wright was to be in charge of infrastructure, but this year Stefan Eriksson was made the new vice-dean of infrastructure, so it is time for a revised job description. Whether her remit will be healthcare issues, which have often landed on the pro-vice-chancellor’s desk in the past, is a matter for further discussion. “The main thing for me is to engage in new issues with the new vice-chancellor, it’s really important to move on,” says Karin Dahlman-Wright, adding: “And I can’t wait to learn some Norwegian!” Ole Petter Ottersen has his own plans for that: “I’ll try to steer clear of the very hardest words, like utdanning and overflate and say utbildning (education) and yta (space) instead,” he says.    Text: Madeleine Svärd Huss Foto: Gustav Mårtensson

Respiratory infections in children often treated unnecessarily with antibiotics

Fri, 19/05/2017 - 18:01
Many childhood virus infections are mistaken for bacterial infection and risk being unnecessarily treated with antibiotics. A new thesis from Karolinska Institutet on respiratory infections in children shows that viruses are a more common cause of serious respiratory infection than previously believed. It is hoped that the research will help to reduce antibiotic use and contribute to new more effective drugs and diagnostic tests. By comparing the viral flora of healthy children at child health centres and children in care for serious respiratory infections, doctoral student Samuel Rhedin has found that viruses are a more common cause of respiratory infection than previously thought. He also charted the incidence of different types of virus, which can facilitate the development of more effective treatments for viral infections. “Our results suggest that we need better treatments for viruses,” says Samuel Rhedin, physician and doctoral student at Karolinska Institutet’s Department of Medicine in Solna. “They can help give the pharmaceutical industry the proper focus for the development of new antiviral drugs. Knowledge of which virus the child has can also give the parents better information on the condition’s prognosis and transmissibility.” Virus common cause of pneumonia Owing to the difficulty of differentiating between viral and bacterial infections, there is a risk that doctors will err on the side of caution and given the children antibiotics, which merely exacerbates the problem of antibiotic resistance. A total of around 1,300 children were studied from 23 child health centres, Sachs’ Children’s Hospital and Astrid Lindgren’s Children’s Hospital. The studies showed that viruses are the more common probable cause of respiratory infections in children, even in those with pneumonia, which has traditionally been considered a bacterial infection. The researchers used the routine diagnostic method PCR (polymerase chain reaction), which has revolutionised the ability to discover and isolate different viruses. The problem with PCR is that it can take days to get a result and that certain viruses are also found in healthy children. The solution to that problem was to take samples from healthy children at child health centres as controls. Evaluating a new blood test “I hope that our results will help to reduce the use of antibiotics and provide incentives to develop new diagnostic tests that are better at distinguishing between viruses and bacteria,” says Dr Rhedin. He and his research group will shortly be starting an evaluation of a new blood test that can diagnose viruses much more quickly. Samuel Rhedin defended his thesis on “Severe viral respiratory tract infections in children” on 12 May 2017. The individual studies have, however, already been frequently cited in the international scientific press.

The Axel Hirsch Prize awarded for research on the history of the Nobel Prize in Physiology or Medicine

Fri, 19/05/2017 - 10:25
Nils Hansson, researcher at Heinrich Heine University in Düsseldorf, is awarded the Axel Hirsch Prize 2017 for his research in Swedish and German archives on candidates for the Nobel Prize in Physiology or Medicine who were not awarded the prize. The award is made by decision of the Board of Research at Karolinska Institutet. Since 2014 Nils Hansson has written 17 articles on this theme, several of which have been published or are in press in recognised scientific journals. “This gratifying news reaches me in Berlin, where I am to give a talk at the Charité university hospital this evening – on the very topic of the history of the Nobel Prize. It’s an important recognition that will stimulate me to continue my research!,” Nils Hansson says. Nils Hansson received his PhD from Lund University in 2013, defending a thesis on medical contact between Sweden and Germany during the Nazi era.  The prize, worth SEK 50,000, will be presented during the installation ceremony on 12 October.

Eva Herweijer is awarded a scholarship for her thesis on HPV vaccination

Fri, 19/05/2017 - 10:18
This year’s recipient of the Sven Gard scholarship for best thesis in virology is Eva Herweijer of the Department of medical epidemiology and biostatistics, MEB. Eva Herweijer is awarded the scholarship, worth SEK 50,000, for her thesis entitled Register-Based Evaluation of HPV Vaccination Programs, where she combines information from various Swedish quality registers and thus contributes important bases for how HPV vaccinations can best be carried out. Because Eva Herweijer’s thesis shows that HPV vaccination is effective against preliminary stages of cervical cancer it will probably lead to greater acceptance of HPV vaccination.